Literature DB >> 20035033

Increment and impairment of adiponectin in renal failure.

Noriyuki Komura1, Shinji Kihara, Mina Sonoda, Norikazu Maeda, Yoshihiro Tochino, Tohru Funahashi, Iichiro Shimomura.   

Abstract

AIMS: Patients with chronic renal failure are at high risk of cardiovascular diseases. Previous studies in healthy population showed that hypoadiponectinemia was associated with high cardiovascular disease risk. However, plasma adiponectin (APN) levels are increased in renal dysfunction. Therefore, the clinical significance of plasma APN level in patients with moderate renal dysfunction is controversial. The aim of this study was to determine the change of plasma APN levels in a mouse model of renal failure and the loss of vasculo-protective function of APN in the presence of high cystatin C levels. METHODS AND
RESULTS: Subtotal (5/6) nephrectomy was performed in APN-knockout (KO) mice and wild-type (WT) mice. The procedure in WT mice resulted in the significant increase of plasma APN and cystatin C levels. The clearance rate of APN was measured by injecting plasma from WT mice into KO mice. The clearance rate was significantly decreased in subtotal nephrectomized KO mice compared with sham-operated KO mice. Adiponectin protein and mRNA levels in adipose tissue were similar to subtotal nephrectomized and sham-operated mice. In cultured endothelial cells, at a high concentration corresponding to renal failure, cystatin C abolished the suppressive effects of APN on tumour necrosis factor alpha-induced expression of monocyte adhesion molecules.
CONCLUSION: Plasma APN increases in chronic renal failure, at least in part due to low clearance rate. High concentrations of cystatin C abolish the vasculo-protective effect of APN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20035033     DOI: 10.1093/cvr/cvp415

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  22 in total

1.  Association between high-molecular-weight adiponectin and bone mineral density in hemodialysis patients.

Authors:  Nobuyuki Amemiya; Shigeru Otsubo; Yuko Iwasa; Takako Onuki; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-11-14       Impact factor: 2.801

2.  Urinary cystatin C as a potential risk marker for cardiovascular disease and chronic kidney disease in patients with obesity and metabolic syndrome.

Authors:  Noriko Satoh-Asahara; Takayoshi Suganami; Takafumi Majima; Kazuhiko Kotani; Yasuhisa Kato; Rika Araki; Kazunori Koyama; Taiichiro Okajima; Makito Tanabe; Mariko Oishi; Akihiro Himeno; Shigeo Kono; Akira Sugawara; Masakazu Hattori; Yoshihiro Ogawa; Akira Shimatsu
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

3.  Relationship between serum cystatin C and serum adiponectin level in type 2 diabetic patients.

Authors:  Yoshiya Hosokawa; Yuya Yamada; Yoshinari Obata; Megu Yamaguchi Baden; Kenji Saisho; Arisa Ihara; Koji Yamamoto; Kiyonori Katsuragi; Yuji Matsuzawa
Journal:  Clin Exp Nephrol       Date:  2011-11-30       Impact factor: 2.801

4.  Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease.

Authors:  Joseph Satriano; Kumar Sharma; Roland C Blantz; Aihua Deng
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-03

5.  Adiponectin-SOGA Dissociation in Type 1 Diabetes.

Authors:  Terry P Combs; Janet K Snell-Bergeon; David M Maahs; Bryan C Bergman; Marie Lamarche; Laura Iberkleid; Omar AbdelBaky; Roland Tisch; Philipp E Scherer; Errol B Marliss
Journal:  J Clin Endocrinol Metab       Date:  2015-06-08       Impact factor: 5.958

6.  Higher levels of adiponectin in vascular endothelial cells are associated with greater brachial artery flow-mediated dilation in older adults.

Authors:  Jeung-Ki Yoo; Moon-Hyon Hwang; Meredith J Luttrell; Han-Kyul Kim; Thomas H Meade; Mark English; Mark S Segal; Demetra D Christou
Journal:  Exp Gerontol       Date:  2015-01-05       Impact factor: 4.032

7.  Adiponectin provides cardiovascular protection in metabolic syndrome.

Authors:  Yoshihisa Okamoto
Journal:  Cardiol Res Pract       Date:  2011-01-23       Impact factor: 1.866

Review 8.  Clinical review: adiponectin biology and its role in inflammation and critical illness.

Authors:  Katherine Robinson; John Prins; Bala Venkatesh
Journal:  Crit Care       Date:  2011-04-20       Impact factor: 9.097

9.  Impaired renal function impacts negatively on vascular stiffness in patients with coronary artery disease.

Authors:  Sabrina H Rossi; Emily P McQuarrie; William H Miller; Ruth M Mackenzie; Jane A Dymott; María U Moreno; Chiara Taurino; Ashley M Miller; Ulf Neisius; Geoffrey A Berg; Zivile Valuckiene; Jonathan A Hannay; Anna F Dominiczak; Christian Delles
Journal:  BMC Nephrol       Date:  2013-08-13       Impact factor: 2.388

10.  Circulating adiponectin is associated with renal function independent of age and serum lipids in west africans.

Authors:  A P Doumatey; J Zhou; H Huang; J Adeleye; W Balogun; O Fasanmade; T Johnson; J Oli; G Okafor; A Amoah; B Eghan; K Agyenim-Boateng; J Acheampong; C Adebamowo; A Adeyemo; C N Rotimi
Journal:  Int J Nephrol       Date:  2012-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.